
Modification of Systemic MTSAD Treatment Protocols in the COVID Pandemic Environment and When Considering COVID Vaccination
Overview and case discussion of COVID-19 infection and vaccination in patients with moderate-to-severe atopic dermatitis. The potential interference of COVID-19 vaccine immunogenicity for patients on biologics and immunosuppressants will be considered. Considerations for modifications of immunosuppressant dosage surrounding current COVID-19 vaccinations will be discussed.








